Spots Global Cancer Trial Database for myeloablative conditioning
Every month we try and update this database with for myeloablative conditioning cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies | NCT02120157 | Myeloablative C... HLA-mismatched ... Graft Survival Transplantation... | Cyclophosphamid... TBI Busulfan Unmanipulated B... Tacrolimus Mycophenolate m... | 6 Months - 25 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | NCT05457556 | Acute Lymphobla... Acute Myeloid L... Mixed Phenotype... Myelodysplastic... | Biospecimen Col... Bone Marrow Asp... Busulfan Cyclophosphamid... Echocardiograph... Fludarabine Haploidentical ... Lapine T-Lympho... Lumbar Puncture Matched Unrelat... Melphalan Methotrexate Multigated Acqu... Mycophenolate M... Myeloablative C... Quality-of-Life... Questionnaire A... Rituximab T-Cell Depletio... Tacrolimus Thiotepa Total-Body Irra... | 6 Months - 21 Years | Children's Oncology Group | |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | NCT05432635 | B-Cell Non-Hodg... Diffuse Large B... Mantle Cell Lym... Recurrent B-Cel... Recurrent Diffu... Recurrent Mantl... Recurrent Trans... Transformed Non... | Anti-CD19-CAR C... Autologous Hema... Multi-peptide C... Myeloablative C... | 18 Years - | City of Hope Medical Center | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML | NCT06267898 | MDS CMML | 18 Years - | European Society for Blood and Marrow Transplantation | ||
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | NCT05432635 | B-Cell Non-Hodg... Diffuse Large B... Mantle Cell Lym... Recurrent B-Cel... Recurrent Diffu... Recurrent Mantl... Recurrent Trans... Transformed Non... | Anti-CD19-CAR C... Autologous Hema... Multi-peptide C... Myeloablative C... | 18 Years - | City of Hope Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
